Hopman Mark sold $681K of BBNX

Beta Bionics, Inc. faces a proposed investor lawsuit over alleged misleading statements about its iLet insulin-delivery system. The FDA found gaps in complaint handling, including 107 severe hypoglycemia reports and 500 cartridge leak complaints. The company denies wrongdoing and plans to defend itself. The lawsuit covers investors who bought shares from July 2025 to February 2026.

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Beta Bionics (BBNX) faces a class action lawsuit after a 37% stock drop following disclosures of medical device safety issues. The lawsuit follows the sharp decline, with potential regulatory or financial impacts yet to be quantified.

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Beta Bionics completed a $172.5 million public offering. The company's stock has seen a 5-day change of 21.43 USD, a 1st Jan change of -3.38%, and a year-to-date change of +29.17%. BofA Securities recently adjusted its price target to $18 from $15.50.

Beta Bionics (BBNX) raised $172.5M in a stock offering, selling 7.65M shares at $17.25 each. Underwriters exercised an option for 1.3M more shares. Proceeds will support Mint commercialization, manufacturing, and R&D. J.P. Morgan and others managed the offering.